We are live on ! Find out more
ABEO icon

Abeona Therapeutics

104 hedge funds and large institutions have $444M invested in Abeona Therapeutics in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

42% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 24

13% more funds holding

Funds holding: 92104 (+12)

8% more call options, than puts

Call options by funds: $2.64M | Put options by funds: $2.44M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.19% less ownership

Funds ownership: 3.09%2.9% (-0.19%)

24% less capital invested

Capital invested by funds: $585M → $444M (-$140M)

Holders
104
Holders Change
+12
Holders Change %
+13.04%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
21
Increased
34
Reduced
24
Closed
8
Calls
$2.64M
Puts
$2.44M
Net Calls
+$200K
Net Calls Change
-$4.61M

ABEO Hedge Fund Activity: Q3 2018 in Review

104 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q3 2018, worth a combined $444M — down 24% from $585M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new ABEO positions and 8 closed out — a net gain of 13 holders — while 34 added to existing stakes and 24 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $11M. The largest seller was Viking Global Investors, cutting an estimated $25.2M.

  • 104 institutional investors held Abeona Therapeutics (ABEO) as of Q3 2018, up from 92 in Q2 2018.
  • Funds reported $444M of Abeona Therapeutics stock for Q3 2018, down 24% quarter-over-quarter.
  • 21 funds opened new Abeona Therapeutics positions in Q3 2018 and 8 closed out, a net change of +13 holders.
  • The largest Abeona Therapeutics buyer in Q3 2018 was Wellington Management Group, an estimated $11M added.
  • The largest Abeona Therapeutics seller in Q3 2018 was Viking Global Investors, an estimated $25.2M sold.

Based on aggregated 13F filings for Q3 2018.